Table 4. Clinical Characteristics Associated With Telangiectasia (Ever) in Patients With ssSSc.
| Characteristics of patients with ssSSc at last visit | Univariate modeling for telangiectasia (ever vs never) | Multivariable modeling for telangiectasia (ever vs never) | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Age at last visit, y | 1.013 (0.997-1.030) | .10 | 0.991 (0.964-1.019) | .51 |
| Sex (reference = female) | 0.721 (0.323-1.606) | .42 | NA | NA |
| Disease duration since RP onset (last visit), y | 1.031 (1.009-1.053) | .006 | 1.057 (1.015-1.101) | .007 |
| RP (reference = never) | <0.001 (<0.001->999.999) | .99 | NA | NA |
| Puffy fingers (reference = never) | 1.013 (0.635-1.616) | .96 | NA | NA |
| Pitting scars (reference = never) | 1.093 (0.680-1.757) | .71 | NA | NA |
| DUs (reference = never) | 0.737 (0.455-1.191) | .21 | NA | NA |
| Joint synovitis (reference = never) | 2.732 (1.366-5.464) | .004 | 2.583 (0.911-7.324) | .07 |
| Tendon friction rubs (reference = never) | 1.759 (0.687-4.504) | .24 | NA | NA |
| CK elevation (reference = never) | 0.743 (0.365-1.512) | .41 | NA | NA |
| Esophageal symptoms (reference = never) | 0.978 (0.586-1.633) | .93 | NA | NA |
| Stomach symptoms (reference = never) | 1.448 (0.904-2.319) | .12 | 0.509 (0.237-1.096) | .08 |
| Intestinal symptoms (reference = never) | 1.872 (1.200-2.921) | .006 | 2.479 (1.185-5.187) | .02 |
| History of scleroderma renal crisis (reference = never) | 1.017 (0.250-4.141) | .98 | NA | NA |
| Proteinuria (reference = never) | 1.050 (0.521-2.116) | .89 | NA | NA |
| Lung fibrosis on radiography or HRCT or presence of ILD (reference = never) | 0.975 (0.618-1.536) | .91 | NA | NA |
| Significant dyspnea (reference = never) | 1.670 (0.851-3.275) | .14 | 1.328 (0.438-4.025) | .62 |
| DLCO (%pred) (last visit) | 0.988 (0.973-1.003) | .11 | NA | NA |
| FVC (%pred) (last visit) | 0.997 (0.985-1.009) | .61 | NA | NA |
| TLC (%pred) (last visit) | 1.009 (0.994-1.024) | .25 | NA | NA |
| sPAP >40 mm Hg (reference = never) | 2.714 (1.091-6.753) | .03 | 2.204 (0.553-8.793) | .26 |
| Pulmonary hypertension (reference = never) | 0.938 (0.500-1.760) | .84 | NA | NA |
| Left ventricular ejection fraction (last visit) | 0.997 (0.944-1.052) | .90 | NA | NA |
| Diastolic heart dysfunction (reference = never) | 4.986 (2.891-8.601) | <.001 | 4.778 (2.060-11.081) | <.001 |
| Conduction block (reference = never) | 1.800 (0.902-3.593) | .10 | 0.634 (0.243-1.656) | .35 |
| EScSG disease activity index (2001) (last visit) | 1.707 (1.131-2.576) | .01 | NA | NA |
| EScSG disease activity index (2016) (last visit) | 1.155 (0.755-1.767) | .51 | NA | NA |
| ANA+ (reference = negative) | 0.647 (0.129-3.255) | .60 | NA | NA |
| ACA+ (reference = negative) | 1.294 (0.822-2.038) | .27 | NA | NA |
| ATA+ (reference = negative) | 0.843 (0.477-1.492) | .56 | NA | NA |
| RNA pol III+ (reference = negative) | 3.036 (0.661-13.954) | .15 | 1.673 (0.312-8.961) | .55 |
| PmScl+ (reference = negative) | 2.247 (0.619-8.152) | .22 | NA | NA |
| U1RNP+ (reference = negative) | 2.653 (0.746-9.431) | .13 | 1.621 (0.303-8.684) | .57 |
| CRP >5 mg/L (reference = never) | 1.464 (0.599-3.575) | .40 | NA | NA |
Abbreviations: ACA, anticentromere antibodies; ANA, antinuclear antibodies; ATA, antitopoisomerase I antibodies; CK, creatine kinase; CRP, C-reactive protein; DLCO, diffusion capacities of carbon monoxide; DUs, digital ulcers; EScSG, European Systemic Sclerosis research group; FVC, forced vital capacity; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; NA, not applicable; %pred, percent predicted; RNA pol III, anti–RNA polymerase III antibodies; RP, Raynaud phenomenon; sPAP, systolic pulmonary arterial pressure; ssSSc, systemic sclerosis sine scleroderma; TLC, total lung capacities; U1RNP, anti–U1 ribonuclease protein antibodies.